CLLS Cellectis
Price (delayed)
$1.645
Market cap
$46.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.41
Enterprise value
$12.46M
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene
Highlights
The company's EPS has surged by 77% YoY and by 63% QoQ
CLLS's net income has surged by 64% year-on-year and by 56% since the previous quarter
CLLS's quick ratio is up by 17% year-on-year but it is down by 2.9% since the previous quarter
The company's debt rose by 3.6% YoY but it fell by 2.2% QoQ
Key stats
What are the main financial stats of CLLS
Market
Valuations
Earnings
Shares outstanding
28M
Market cap
$46.06M
Enterprise value
$12.46M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.26
Price to sales (P/S)
3.35
EV/EBIT
N/A
EV/EBITDA
2.65
EV/Sales
0.25
Revenue
$49.22M
Gross profit
$49.22M
Operating income
-$59.56M
Net income
-$36.76M
EBIT
-$15.15M
EBITDA
$4.7M
Free cash flow
$20.41M
Per share
Balance sheet
Liquidity
EPS
-$0.41
EPS diluted
-$0.41
Free cash flow per share
$0.2
Book value per share
$1.31
Revenue per share
$0.49
TBVPS
$3.82
Total assets
$383.54M
Total liabilities
$252.51M
Debt
$109.65M
Equity
$131.03M
Working capital
$120.8M
Debt to equity
0.84
Current ratio
1.73
Quick ratio
1.69
Net debt/EBITDA
-7.15
Margins
Efficiency
Dividend
EBITDA margin
9.5%
Gross margin
100%
Net margin
-74.7%
Operating margin
-121%
Return on assets
-9.5%
Return on equity
-29.4%
Return on invested capital
-9%
Return on capital employed
-7%
Return on sales
-30.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLLS stock price
How has the Cellectis stock price performed over time
Intraday
3.46%
1 week
12.67%
1 month
29.53%
1 year
-35.74%
YTD
-8.61%
QTD
32.66%
Financial performance
How have Cellectis's revenue and profit performed over time
Revenue
$49.22M
Gross profit
$49.22M
Operating income
-$59.56M
Net income
-$36.76M
Gross margin
100%
Net margin
-74.7%
The company's net margin has surged by 93% YoY and by 68% QoQ
Cellectis's operating margin has soared by 89% YoY and by 44% from the previous quarter
CLLS's net income has surged by 64% year-on-year and by 56% since the previous quarter
The company's operating income rose by 39% YoY and by 24% QoQ
Growth
What is Cellectis's growth rate over time
Valuation
What is Cellectis stock price valuation
P/E
N/A
P/B
1.26
P/S
3.35
EV/EBIT
N/A
EV/EBITDA
2.65
EV/Sales
0.25
The company's EPS has surged by 77% YoY and by 63% QoQ
CLLS's equity has surged by 55% year-on-year
The P/B is 26% less than the 5-year quarterly average of 1.7 and 10% less than the last 4 quarters average of 1.4
The price to sales (P/S) is 74% lower than the 5-year quarterly average of 13.1 and 61% lower than the last 4 quarters average of 8.5
The revenue is up by 37% from the previous quarter
Efficiency
How efficient is Cellectis business performance
The company's return on sales has surged by 95% YoY and by 66% QoQ
CLLS's ROA has soared by 76% year-on-year and by 58% since the previous quarter
The return on equity has surged by 73% year-on-year and by 61% since the previous quarter
CLLS's return on invested capital has surged by 72% year-on-year and by 55% since the previous quarter
Dividends
What is CLLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLLS.
Financial health
How did Cellectis financials performed over time
CLLS's total assets is 52% greater than its total liabilities
CLLS's quick ratio is up by 17% year-on-year but it is down by 2.9% since the previous quarter
CLLS's total assets is up by 15% year-on-year but it is down by 3.1% since the previous quarter
The company's debt is 16% lower than its equity
CLLS's equity has surged by 55% year-on-year
CLLS's debt to equity is down by 33% year-on-year and by 3.4% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.